366 related articles for article (PubMed ID: 31905715)
21. Has resveratrol a potential for mucopolysaccharidosis treatment?
Rintz E; Pierzynowska K; Podlacha M; Węgrzyn G
Eur J Pharmacol; 2020 Dec; 888():173534. PubMed ID: 32877657
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses.
Safary A; Moghaddas-Sani H; Akbarzadeh-Khiavi M; Khabbazzi A; Rafi MA; Omidi Y
Expert Opin Biol Ther; 2021 Sep; 21(9):1181-1197. PubMed ID: 33653197
[TBL] [Abstract][Full Text] [Related]
23. Treating lysosomal storage disorders: What have we learnt?
Lachmann RH
J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
[TBL] [Abstract][Full Text] [Related]
24. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
Lau AA; Hemsley KM
J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
[TBL] [Abstract][Full Text] [Related]
25. MPSBase: Comprehensive repository of differentially expressed genes for mucopolysaccharidoses.
Soares LDF; Villalba Silva GC; Kubaski F; Giugliani R; Matte U
Mol Genet Metab; 2021 Aug; 133(4):372-377. PubMed ID: 34147352
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of dipeptidyl peptidase-IV (DPP-IV) activity in patients with mucopolysaccharidoses types I and II on enzyme replacement therapy - Results of a pilot study.
Hetmańczyk K; Bednarska-Makaruk M; Kierus K; Murawska-Izdebska S; Piekutowska-Abramczuk D; Pilch B; Tylki-Szymańska A; Ługowska A
Clin Biochem; 2016 Apr; 49(6):458-462. PubMed ID: 26592960
[TBL] [Abstract][Full Text] [Related]
27. Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI.
Baldo G; Matte U; Artigalas O; Schwartz IV; Burin MG; Ribeiro E; Horovitz D; Magalhaes TP; Elleder M; Giugliani R
Mol Genet Metab; 2011 Jun; 103(2):197-8. PubMed ID: 21427013
[TBL] [Abstract][Full Text] [Related]
28. From bedside to cell biology: a century of history on lysosomal dysfunction.
Coutinho MF; Matos L; Alves S
Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
Parenti G; Andria G; Valenzano KJ
Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
[TBL] [Abstract][Full Text] [Related]
30. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
Muenzer J
Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
[TBL] [Abstract][Full Text] [Related]
31. The Role of Dimethyl Sulfoxide (DMSO) in Gene Expression Modulation and Glycosaminoglycan Metabolism in Lysosomal Storage Disorders on an Example of Mucopolysaccharidosis.
Moskot M; Jakóbkiewicz-Banecka J; Kloska A; Piotrowska E; Narajczyk M; Gabig-Cimińska M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646511
[TBL] [Abstract][Full Text] [Related]
32. Adenotonsillar pathology in mucopolysaccharidoses - lysosomal storage predominates in paracortical CD63+ cells.
Murgasova L; Hulkova H; Baresova V; Jurovcik M; Stritesky J; Jurickova K; Magner M; Sikora J
Virchows Arch; 2024 Jan; 484(1):135-140. PubMed ID: 37787787
[TBL] [Abstract][Full Text] [Related]
33. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
Parenti G
EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
[TBL] [Abstract][Full Text] [Related]
34. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
35. Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.
Chan MJ; Liao HC; Gelb MH; Chuang CK; Liu MY; Chen HJ; Kao SM; Lin HY; Huang YH; Kumar AB; Chennamaneni NK; Pendem N; Lin SP; Chiang CC
J Pediatr; 2019 Feb; 205():176-182. PubMed ID: 30409495
[TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II.
Uttarilli A; Ranganath P; Matta D; Md Nurul Jain J; Prasad K; Babu AS; Girisha KM; Verma IC; Phadke SR; Mandal K; Puri RD; Aggarwal S; Danda S; Sankar VH; Kapoor S; Bhat M; Gowrishankar K; Hasan AQ; Nair M; Nampoothiri S; Dalal A
Clin Genet; 2016 Dec; 90(6):496-508. PubMed ID: 27146977
[TBL] [Abstract][Full Text] [Related]
37. Gene therapy for Mucopolysaccharidoses.
Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
[TBL] [Abstract][Full Text] [Related]
38. Substrate reduction therapies for mucopolysaccharidoses.
Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G
Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626
[TBL] [Abstract][Full Text] [Related]
39. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
40. Biochemical and molecular analysis of mucopolysaccharidoses in Turkey.
Emre S; Terzioğlu M; Coşkun T; Tokath A; Ozalp I; Müller V; Hopwood J
Turk J Pediatr; 2002; 44(1):13-7. PubMed ID: 11858372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
